Overview
The aim of the PI-PEG study is to explore the taste functions of the following 3 groups of
- participants
-
- healthy volunteers
- patients with early Parkinson's disease
- patients with incipient Lewy body disease.
To this end, the results obtained from taste evoked potentials in each of the 3 groups of participants will be compared with each other and with different nutritional, motor and cognitive data.
This study could reveal a difference in cortical processing of gustatory sensory information between patients who have had idiopathic Parkinson's disease progressing for 3 years or less, and patients who have had Lewy body disease progressing for 3 years or less. Indeed, a modification of taste evoked potentials (in terms of latencies) proportional to the degree of cerebral degeneration could be observed.
Eligibility
Inclusion Criteria:
Healthy volunteers:
- Person who has given written consent
- Adult
- Enrolled in the national register of healthy volunteers
- Fasting > 2 hours before PEG measurement
- Body Mass Index (BMI) < 30 kg/m².
- No cognitive complaints and normal neurological assessment
Patients with idiopathic Parkinson's disease:
- Person who has given written consent
- Adult
- Fasting > 2 hours before PEG measurement
- Body Mass Index (BMI) < 30 kg/m².
- Diagnostic criteria for established or probable IPD
Patients with Lewy body disease:
- Person who has given written consent
- Adult
- Fasting > 2 hours prior to PEG measurement
- Body Mass Index (BMI) < 30 kg/m².
- Diagnostic criteria for probable or possible LBD
Exclusion Criteria:
- Non-affiliated to national health insurance
- Person under legal protection (curatorship, guardianship)
- Person subject to a court order
- Pregnant, parturient or breast-feeding women
- Major unable to give consent
- MMSE score < 15 and/or MoCA < 10
- Known infection with COVID-19 in the 6 months prior to inclusion
- Active smoker (> 4 cigarettes per day on a regular basis)
- Subject with pacemaker (contraindication for bioelectrical impedancemetry)
- Diabetic (type 1 or type 2)
- Taking medication (in progress at the time of the study) that interferes with gustation